Carbidopa
Code | Size | Price |
---|
TAR-T6795-1mL | 1 mL * 10 mM (in DMSO) | £111.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T6795-25mg | 25mg | £136.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T6795-100mg | 100mg | £213.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Images
Documents
Further Information
Bioactivity:
Carbidopa is an aromatic-L-amino-acid decarboxylase inhibitor (IC50: 29?2 μM). It is used in PARKINSON DISEASE to reduce peripheral adverse effects of LEVODOPA.
CAS:
28860-95-9
Formula:
C10H14N2O4
Molecular Weight:
226.232
Pathway:
Immunology/Inflammation; Metabolism;
Purity:
0.9801
SMILES:
C[C@@](Cc1ccc(O)c(O)c1)(NN)C(O)=O
Target:
Decarboxylase; Aryl Hydrocarbon Receptor
References
Han L, Song B, Zhang P, et al.PC3T: a signature-driven predictor of chemical compounds for cellular transition.Communications Biology.2023, 6(1): 989.
Orlefors, H., et al., Carbidopa pretreatment improves image interpretation and visualisation of carcinoid tumours with 11C-5-hydroxytryptophan positron emission tomography. Eur J Nucl Med Mol Imaging, 2006. 33(1): p. 60-5.
Durso, R., et al., Variable absorption of carbidopa affects both peripheral and central levodopa metabolism. J Clin Pharmacol, 2000. 40(8): p. 854-60.